

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify⦠read more
Healthcare
Biotechnology
13 years
USD
Exclusive to Premium users
$12.95
Price+2.78%
$0.35
$376.565m
Small
-
Premium
Premium
-49.9%
EBITDA Margin-76.3%
Net Profit Margin-41.8%
Free Cash Flow Margin-49.9%
EBITDA Margin-76.3%
Net Profit Margin-41.8%
Free Cash Flow Margin$69.213m
+6.0%
1y CAGR-4.0%
3y CAGR-5.0%
5y CAGR-$61.984m
+24.3%
1y CAGR+22.3%
3y CAGR+14.3%
5y CAGR-$2.74
+28.7%
1y CAGR+24.2%
3y CAGR+16.2%
5y CAGR$116.587m
$314.704m
Assets$198.117m
Liabilities$186.617m
Debt59.3%
-4x
Debt to EBITDA-$9.609m
+70.1%
1y CAGR+50.2%
3y CAGR+30.4%
5y CAGR